<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40921316</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5867</ISSN><JournalIssue CitedMedium="Internet"><Volume>223</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Steroids</Title><ISOAbbreviation>Steroids</ISOAbbreviation></Journal><ArticleTitle>Vitamin D potentiation of metformin hepatoprotective activities: Concurrent targeting of carbohydrate enzymatic pathways and PCSK9/AGEs-regulated oxidative stress mechanisms in type 2 diabetic male Wistar rats.</ArticleTitle><Pagination><StartPage>109685</StartPage><MedlinePgn>109685</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.steroids.2025.109685</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0039-128X(25)00126-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Emerging evidence indicates that metformin-based combination therapy may offer better glycemic control and improved tolerability compared to diabetes monotherapy. Building on this, vitamin D was considered a potential adjunct to metformin for managing type 2 diabetes. Although vitamin D is primarily recognized for its role in calcium regulation, it also appears to influence glucose metabolism and other non-skeletal functions. Therefore, this study was designed to evaluate the hepatoprotective effects of vitamin D and metformin in diabetic rats.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">Thirty (30) male Wistar rats were randomized into five treatment groups as follows: control, diabetes (DM) untreated, DM treated with vitamin D (25&#xa0;&#xb5;g/kg), DM treated with metformin (180&#xa0;mg/kg), and DM treated with both vitamin D (25&#xa0;&#xb5;g/kg) and metformin (180&#xa0;mg/kg). All treatments were via the oral route and lasted for 28&#xa0;days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Vitamin D and/or metformin improved glucose and lipid imbalances caused by diabetes. These benefits were linked to enhanced activity of key liver enzymes involved in glucose metabolism, including hexokinase, phosphofructokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase, G-6-phosphatase, and lactate dehydrogenase. Additionally, treatment with vitamin D and/or metformin counteracted diabetes-induced increases in pro-oxidant levels, restored both enzymatic and non-enzymatic antioxidant defenses, and reduced inflammation. This oxido-inflammatory response appeared to be connected to oxidative signaling mediated by proprotein convertase subtilisin/kexin type 9 (PCSK9), highlighting a potential mechanism underlying the protective effects of these therapies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Vitamin D enhanced the antidiabetic effects of metformin by further improving the activity of carbohydrate-metabolizing enzymes and modulating PCSK9-mediated oxidative signaling. This suggests that vitamin D can boost metformin's efficacy in regulating glucose-lipid metabolism and reducing oxidative stress in diabetes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdulrahim</LastName><ForeName>Halimat Amin</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odetayo</LastName><ForeName>Adeyemi Fatai</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Physiology, Federal University of Health Sciences, Ila-Orangun, Nigeria; Endocrinology, Reproductive, and Metabolism Unit, Federal University of Health Sciences, Ila-Orangun, Nigeria. Electronic address: adeyemi.odetayo@fuhsi.edu.ng.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amosa</LastName><ForeName>Muhammad Bashir</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olumoye</LastName><ForeName>John Oluwapelumi</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Wasiu Abiodun</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebadan</LastName><ForeName>Ivan Ayomide</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Kehinde Yusuf</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abodunrin</LastName><ForeName>Gloria Toluwase</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adefolarin</LastName><ForeName>Samuel Oluwaseyi</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajibare</LastName><ForeName>Ayodeji Johnson</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Physiology, Lead City University, Ibadan, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olatunji</LastName><ForeName>Temilade</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdussalam</LastName><ForeName>Tahir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okesina</LastName><ForeName>Kazeem Bidemi</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Rwanda, Kigali, Rwanda. Electronic address: adeyemiodetayo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olayaki</LastName><ForeName>Luqman Aribidesi</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Steroids</MedlineTA><NlmUniqueID>0404536</NlmUniqueID><ISSNLinking>0039-128X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antioxidant defense</Keyword><Keyword MajorTopicYN="N">Combination therapy</Keyword><Keyword MajorTopicYN="N">Glucose metabolism</Keyword><Keyword MajorTopicYN="N">Insulin resistance</Keyword><Keyword MajorTopicYN="N">Liver dysfunction</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes complications</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40921316</ArticleId><ArticleId IdType="doi">10.1016/j.steroids.2025.109685</ArticleId><ArticleId IdType="pii">S0039-128X(25)00126-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>